Proactive Investors USA Sits Down with Hemispherx CEO Thomas K. Equels

Hemispherx has been making major strides in its immuno-oncology work studying the effects of Ampligen in the treatment of nine different cancer types. We recently provided stockholders, investors and financiers with a detailed update on our clinical studies and programs. Our CEO, Thomas K. Equels, spoke with Christine Corrado of Proactive Investors USA to update her audience on the same. Watch the full interview here.

Hemispherx News 06

Need More Info?

Let’s Talk